Could blood from a cancer's own vein reveal more tumor DNA?
NCT ID NCT05497531
First seen Feb 26, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This pilot study compares two ways of collecting blood to find circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is to see if the tumor-draining vein sample contains more or different ctDNA. Only 15 participants are needed for this early-stage study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a more sensitive way to detect tumor DNA, potentially improving cancer monitoring and treatment decisions.
What could go wrong
This is a very small pilot study (15 people) and only tests a blood collection method, not a treatment. It may not show a meaningful difference or be practical for wider use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.